Please use this identifier to cite or link to this item:
https://hdl.handle.net/10419/322146
Authors:
Year of Publication:
2025
Series/Report no.:
Texto para Discussão No. 3119
Version Description:
Versão atualizada em 23 de junho de 2025.
Publisher:
Instituto de Pesquisa Econômica Aplicada (IPEA), Brasília
Abstract (Translated):
This text aims to analyze the expenditures on litigated pharmaceuticals by the municipalities and states participating in the Unified Health System (SUS)' Pharmaceutical Service Research and to discuss the process of health judicialization in this system. Issues related to pharmaceuticals judicialization are included in the research questionnaire, which was conducted by Ipea in partnership with the National Council of Municipal Health Departments (Conasems) and National Council of Health Secretaries (Conass) in 2024. In this study, data were collected from municipalities, the Federal District, and states regarding the management and financing of this area between 2019 and 2023. The data on expenditures for litigated pharmaceuticals were processed to eliminate outliers, and the analysis was conducted by government sphere and geographical region, using basic descriptive statistics to summarize the main findings. A high prevalence of judicial demands for pharmaceuticals was found among municipalities (58.7%) and states (100%), as well as the provision of pharmaceutical products not registered with the National Health Surveillance Agency (Anvisa) and off-label, and the implementation of administrative procedures for dispensing pharmaceuticals not incorporated into the SUS. In 2023, on average, expenditure on litigated pharmaceuticals consumed 8.4% and 32.9% of the total pharmaceutical expenditure in the municipalities and states participating in the study, respectively. The results highlight the widespread judicialization in SUS, with significant impacts on the budgets of subnational entities, particularly the states, and the potential to exacerbate inequalities in access to pharmaceuticals and health inequities in Brazil.
Subjects:
health' judicialization
pharmaceutical service
pharmaceutical expenditure
health expenditure
Unified Health System
pharmaceutical service
pharmaceutical expenditure
health expenditure
Unified Health System
JEL:
H51
Persistent Identifier of the first edition:
Additional Information:
ERRATA: Prezados/as leitores/as, Após a publicação original deste texto em 27 de maio de 2025, foram identificados pontos que necessitaram de correção. Em 23 de junho de 2025, foram realizados ajustes nas páginas 10 (terceiro parágrafo) e 33 (terceiro parágrafo). Agradecemos a compreensão e pedimos desculpas pelos eventuais transtornos causados.
Document Type:
Working Paper
Appears in Collections:
Files in This Item:
File
Description
Size
Format
Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.